Recent genomic efforts, including those by the NIH Pediatric Cardiac Genomics Consortium (PCGC), have expanded the landscape of CHD-associated genes and revealed multiple de novo variants in NAT complex components, with NAA15 and NAA16 among the most frequently affected [11,12,13]. This evidence concerns the gene BRD2 and coronary artery disorder.